Sign in

You're signed outSign in or to get full access.

TB

Theriva Biologics, Inc. (TOVX)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 EPS materially beat Wall Street consensus: reported EPS of $(1.55) versus consensus of $(4.19), driven by lower operating expenses and interest income; revenue remained de minimis as the company is pre-commercial. The quarter also featured pivotal clinical data from VIRAGE showing statistically significant PFS and DoR improvements, with OS meeting the primary endpoint (HR=0.57; p=0.0546).
  • VIRAGE Phase 2b topline showed VCN-01 + gemcitabine/nab-paclitaxel improved median OS to 10.8 months (vs 8.6), PFS to 7.0 months (vs 4.6), and doubled DoR to 11.2 months (vs 5.4); benefit was larger in two-dose subgroup (OS 14.8 vs 11.6; HR=0.44; p=0.046). These results underpinned plans to finalize Phase 3 design.
  • Cash runway extended into Q1 2026 following a May 8 offering that lifted cash to $14.1 million; Q1 quarter-end cash was $10.0 million. Management intends to prioritize manufacturing scale-up of VCN-01 and Phase 3 preparations.
  • Expected near-term catalysts: End-of-Phase 2 FDA meeting, Phase 3 protocol finalization, and continued regulatory engagement; narrative suggests potential partner engagement following hazard ratio profile.

What Went Well and What Went Wrong

What Went Well

  • VIRAGE met primary survival and safety endpoints: median OS increased to 10.8 months (HR=0.57; p=0.0546), PFS to 7.0 months (HR=0.55; p=0.0105), and DoR doubled to 11.2 months (HR=0.22; p=0.0035). “The significantly reduced hazard ratios for survival parameters... provide compelling evidence” of benefit in metastatic PDAC.
  • Two-dose regimen appeared to enhance outcomes: in patients reaching Cycle 4 (two doses of VCN-01), OS rose to 14.8 months vs 11.6 (HR=0.44; p=0.046), with improved PFS (11.2 vs 7.4; HR=0.48; p=0.0173). Safety after the second dose showed fewer and lower-grade events.
  • Cost discipline: G&A fell 25% YoY to $1.4 million; R&D decreased 14% YoY to $3.0 million, reflecting lower indirect VCN-01 manufacturing and reduced SYN-004 trial expenses, partially offset by VIRAGE and SYN-020 costs.

Management quote: “We have started 2025 with outstanding clinical progress… [VIRAGE] achieved its primary survival and safety endpoints, highlighting the potential therapeutic benefits of our oncolytic virus platform.” — Steven A. Shallcross, CEO/CFO.

What Went Wrong

  • Continued net losses and minimal operating income sources: net loss was $(4.3) million; other income fell to $93k (vs $227k YoY), reflecting lower interest income.
  • Balance sheet compression pre-offering: cash declined to $10.0 million at quarter end (from $11.6 million at 12/31/24) before the capital raise; stockholders’ equity decreased to $15.5 million (from $19.1 million at 12/31/24).
  • Ongoing financing dependency and execution risk: Phase 3 start is contingent on financing; leadership guided to potential Phase 3 initiation mid-2026, subject to funding and regulatory alignment.

Financial Results

EPS vs Estimates and Prior Periods

MetricQ3 2024Q1 2025
EPS ($USD) Actual$(6.81) $(1.55)
EPS Consensus Mean*$(7.25)*$(4.19)*

Values marked with * retrieved from S&P Global.

Operating Costs and Net Loss (YoY)

Metric ($USD Millions)Q1 2024Q1 2025
General & Administrative$1.93 $1.45
Research & Development$3.46 $2.97
Other Income$0.23 $0.09
Net Loss$(5.17) $(4.32)
EPS ($USD)$(7.53) $(1.55)

Balance Sheet Liquidity

Metric ($USD Millions)Dec 31, 2024Mar 31, 2025
Cash & Cash Equivalents$11.61 $10.01

Subsequent event: cash balance $14.1 million post May 8 offering.

Clinical KPIs (VIRAGE Phase 2b, Full Analysis Set unless noted)

KPIControl (SoC)VCN-01 + SoCHazard Ratio (95% CI)p-value
Median OS (months)8.6 10.8 0.57 (0.34–0.96) 0.0546
Median PFS (months)4.6 7.0 0.55 (0.34–0.88) 0.0105
Median DoR (months)5.4 11.2 0.22 (0.08–0.62) 0.0035
Two-dose subgroup OS (months)11.6 14.8 0.44 (0.21–0.92) 0.046
Two-dose subgroup PFS (months)7.411.20.48 (0.25–0.91)0.0173

Safety note: AEs were transient/reversible; fewer and lower grade after second dose per DMC review.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayCorporateRunway into Q3 2025 (as of 12/31/24) Runway into Q1 2026 (post May 8 offering) Raised runway
R&D Expense Trend2025Anticipated increase with VIRAGE completion, Phase 3 prep (FY24) Anticipated increase as Phase 3 planning, RB program, GMP scale-up proceed (Q1 2025) Maintained upward trend
Manufacturing Scale-up (VCN-01)2025Advancing proprietary suspension cell line; Spanish funding Scaling up manufacturing for Phase 3; use of offering proceeds Accelerating activity
Regulatory Path2025FDA/EMA guidance on Phase 3; EOP2 meeting planned before end-2025 Finalizing Phase 3 design; planning End-of-Phase 2 FDA meeting Maintained timeline
Financing2025-2026N/APhase 3 start target mid-2026 contingent on financing New timing disclosure

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024, Q4 2024)Current Period (Q1 2025)Trend
Regulatory/Phase 3 PathAchieved FDA Fast Track; EMA/FDA guidance on Phase 3; EOP2 planned before end-2025 Phase 3 design being finalized; blinded, randomized design suggested; EOP2 meeting planned Execution progressing
Manufacturing Scale-upSpanish National Knowledge Transfer funding; plans to scale proprietary suspension cell line Offering proceeds earmarked for GMP scale-up; active planning for Phase 3 supply Accelerating
Product Performance (VCN-01)Enrollment completed; strong Phase 1 signals; KOL support VIRAGE met survival/safety endpoints; stronger benefit with two-dose regimen Positive momentum
R&D ExecutionSYN-004 Cohort 2 completed; Cohort 3 contingent on funding SYN-004 presented at ESCMID; continued support; R&D spend expected to rise Focused on VCN-01
Financing/MacroSmall raise; runway compression pre-offering $7.5M offering; runway extended to Q1 2026 Improved liquidity
Retinoblastoma StrategyOrphan/Rare pediatric designations; Phase 1 positive; CSR in prep Advancing pivotal protocol discussions Steady progress

Management Commentary

  • “The VIRAGE Phase 2b clinical trial of VCN-01… achieved its primary survival and safety endpoints, highlighting the potential therapeutic benefits of our oncolytic virus platform.” — Steven A. Shallcross, CEO/CFO.
  • “The significantly reduced hazard ratios for survival parameters in the VCN-01 treatment group provide compelling evidence that VCN-01 in combination with gemcitabine/nab-paclitaxel may extend the lives of metastatic PDAC patients… expected to enable the design of a Phase 3 confirmatory trial.” — Steven A. Shallcross.
  • Regulatory design notes: randomized comparison vs gem/nab-paclitaxel; potential blinding; macro cycles concept with repeated VCN-01 dosing while no progression.

Q&A Highlights

  • Phase 3 Timing: Management indicated a potential Phase 3 start “around 1 year from now,” targeting mid-2026, contingent on financing and regulatory alignment.
  • Trial Design: Regulators suggested a blinded trial; consideration of repeated “macro cycles” of VCN-01 dosing with chemotherapy while progression-free.
  • Dosing/Safety: Second-dose safety profile appeared less frequent and lower grade versus first dose, supporting multi-dose strategies.

Estimates Context

  • Q1 2025: Reported EPS $(1.55) versus consensus $(4.19)* — a positive surprise. Revenue consensus remained $0.0*. *
  • Q3 2024: Reported EPS $(6.81) versus consensus $(7.25)* — modest beat. *
  • Coverage depth is thin (one estimate), which may amplify realized-to-estimate variance; forward adjustments likely to reflect clinical de-risking and financing runway extension.

Values marked with * retrieved from S&P Global.

Key Takeaways for Investors

  • The VIRAGE data materially de-risk VCN-01 in first-line metastatic PDAC, with clinically meaningful hazard ratios and a stronger signal in two-dose recipients; expect partner interest and regulatory momentum.
  • Liquidity improved post-offering, extending runway to Q1 2026 and enabling Phase 3 manufacturing scale-up; near-term financing overhang is reduced.
  • EPS beat versus consensus reflects leaner OpEx and interest income, but the investment case remains clinically driven; updates to street models should incorporate higher R&D ahead of Phase 3. *
  • Watch for End-of-Phase 2 outcomes and Phase 3 protocol details (blinding, dosing cadence), which will frame registrational risk and timelines.
  • Strategic optionality across retinoblastoma and SYN-004 persists, but capital allocation is clearly prioritizing VCN-01 PDAC.
  • Trading implications: positive data and extended runway are supportive; catalysts into 2H 2025 (EOP2 meeting) and 2026 (Phase 3 start) can drive re-rating; financing contingency remains a swing factor.